Voriconazole treatment for less-common, emerging, or refractory fungal infections.
By J. Perfect, K. Marr, T. Walsh, R. Greenberg, B. Dupont, J. de la Torre-Cisneros, G. Just-Nübling, H. Schlamm, I. Lutsar, A. Espinel-Ingroff and 1 more. Clinical Infectious Diseases, 2003
671 citations recorded by the source corpus.
Subfields: Epidemiology, Infectious Diseases, Ophthalmology
View Paper: https://www.semanticscholar.org/paper/137bcb4b6e11b043a50494d224a945d3cef50559
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Infectious Diseases
Citations in the corpus
- Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. (2004, neutral): “studies of salvage therapy with voriconazole [18, 19, 36].”
- Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus (2004, background): “Among the new triazoles, only modest activity is seen in vitro (Table 4); however, voriconazole has successfully been used in some patients with amphotericin B-refractory fusariosis (79).”
- Epidemiology of Invasive Mycoses in North America (2010, background): “, Bipolaris, Cladophialophora, and Alternaria) filamentous fungi are being reported with greater frequency (Alastruey-Izquierdo et al. 2008; Herbrecht et al. 2002b; Negroni et al. 2004; Nucci et al. 2007; O’Donnell et al. 2008; Perfect et al. 2003; Pfaller et al. 2004a; Revankar et al. 2002; Revanka”
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America (2010, background): “The former have been studied clinically in salvage situations [18, 19], and the latter have no in vivo activity versus Cryptococcus species.”
- Fusarium Infections in Immunocompromised Patients (2007, background): “In another study, voriconazole was given to 11 patients with fusariosis, all intolerant or refractory to primary therapy (84).”
- Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management (2005, background): “and the dematiaceous fungi, but has no clinically relevant activity against the agents of mucormycosis (34, 117, 120, 147).”
- Histoplasmosis: a Clinical and Laboratory Update (2007, background): “Voriconazole, which is similar to fluconazole in structure, has resulted in success in the treatment of a few patients (37, 100).”